Literature DB >> 8132404

Perfluorooctylbromide (PFOB) as a vitreous substitute in non-human primates.

M D Conway1, G A Peyman, M Karaçorlu, N Bhatt, K F Soike, L C Clark, R E Hoffmann.   

Abstract

We evaluated the toxicity of perfluorooctylbromide in the primate eye as a short-term postoperative vitreous substitute. Four eyes of 4 African green monkeys underwent complete vitrectomy and vitreous replacement with 1.5-2.0 ml of PFOB. One additional animal received BSS as a control vitreous substitute in one eye. Animals were examined twice weekly for clarity and consistency of the vitreous replacement substance. Anterior segment and lenses remained clear in all eyes, although in the immediate postoperative period one eye became inflamed and had a culture-negative vitritis. The other eyes showed a minimal anticipated postoperative vitreous inflammation. Emulsification of the PFOB began within 3 days of injection and progressed up to 3 weeks, precluding fundus examination and fluorescein angiography after 2 weeks. Eyes were enucleated and light microscopy performed at 2 days, 10 days, 33 days, and 45 days. No toxic effects to the retinal cells were detectable by histological examination, but perivasculitis of retinal vessels was noted at 45 days. Indirect examination was normal up to 10 days; thereafter, the fundus view was obscured by the emulsified PFOB. Because of cellular migration into the vitreous cavity and retinal perivasculitis, observed histologically, PFOB seems most suitable for intraoperative rather than postoperative use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8132404     DOI: 10.1007/bf01007793

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  11 in total

1.  Long-term vitreous replacement in primates with intravitreal Vitreon or Vitreon plus silicone.

Authors:  G A Peyman; M D Conway; K F Soike; L C Clark
Journal:  Ophthalmic Surg       Date:  1991-11

2.  Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide.

Authors:  J N Bruneton; M N Falewée; E François; P Cambon; C Philip; J G Riess; C Balu-Maestro; A Rogopoulos
Journal:  Radiology       Date:  1989-01       Impact factor: 11.105

Review 3.  An overview of perfluoroctylbromide--application as a synthetic oxygen carrier and imaging agent for X-ray, ultrasound and nuclear magnetic resonance.

Authors:  D M Long; D C Long; R F Mattrey; R A Long; A R Burgan; W C Herrick; D F Shellhamer
Journal:  Biomater Artif Cells Artif Organs       Date:  1988

4.  Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids.

Authors:  S Chang; H Lincoff; N J Zimmerman; W Fuchs
Journal:  Arch Ophthalmol       Date:  1989-05

5.  Experimental evaluation of perfluorophenanthrene as a high specific gravity vitreous substitute: a preliminary report.

Authors:  M Nabih; G A Peyman; L C Clark; R E Hoffman; M Miceli; M Abou-Steit; M Tawakol; K R Liu
Journal:  Ophthalmic Surg       Date:  1989-04

6.  Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure.

Authors:  L C Clark; F Gollan
Journal:  Science       Date:  1966-06-24       Impact factor: 47.728

7.  Experimental vitreous replacement with perfluorotributylamine.

Authors:  S Chang; N J Zimmerman; T Iwamoto; R Ortiz; D Faris
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

8.  Perfluoroctylbromide. Acute hemodynamic effects, in pigs, of intravenous administration compared with the standard ionic contrast media.

Authors:  W W Peck; R F Mattrey; R A Slutsky; C B Higgins
Journal:  Invest Radiol       Date:  1984 Mar-Apr       Impact factor: 6.016

9.  Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material.

Authors:  R F Mattrey; F W Scheible; B B Gosink; G R Leopold; D M Long; C B Higgins
Journal:  Radiology       Date:  1982-12       Impact factor: 11.105

10.  Perfluorocarbon liquids in the management of traumatic retinal detachments.

Authors:  S Chang; V Reppucci; N J Zimmerman; M H Heinemann; D J Coleman
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.